Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exemed Receives CDSCO Nod For Study of Sacubitril Plus Valsartan Sustained-Release Tablet
Details : Sacubright (sacubitril and valsartan) is an oral angiotensin receptor neprilysin inhibitor, which is approved for the treatment of chronic heart failure in 2 years and older patients.
Product Name : Sacubright
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2024
Lead Product(s) : Sacubitril Sodium,Valsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glimepiride,Empagliflozin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exemed gets CDSCO Nod to Study Empagliflozin, Glimepiride & Metformin FDC
Details : Empagliflozin, metformin and glimepiride fixed dose combination is being evaluated for the treatment of patients with type 2 diabetes.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2024
Lead Product(s) : Glimepiride,Empagliflozin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
